Company intelligence / Profile preview

Transave, Inc.

Monmouth Junction, New Jersey, United Statestransaveuk.co.uk ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Transave developed Arikace (liposomal amikacin for inhalation), which completed Phase II trials for treating pseudomonas lung infections in cystic fibrosis patients with promising results before the company was acquired by Insmed.

Therapeutic areas: PulmonologyOncologyInfectious Diseases
Modalities: Inhaled antibioticsliposomal drug delivery
Industry: Biotech

Drug pipeline

1 asset

amikacin

Phase 2

Indications: Cystic fibrosis, Pseudomonas lung infections, Bronchiectasis

Partnerships

Cystic Fibrosis Foundation (received $1.7 million award)

Beyond the preview

Go deeper on Transave, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transave, Inc..

Explore the full profile